After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
EyePoint Pharmaceuticals Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of EyePoint Pharmaceuticals Inc is $1.06B. A total of 0.58 million shares were traded on the day, compared to an average of 946.03K shares.
In the most recent transaction, Jones David Scott sold 209 shares of EYPT for 28.49 per share on Feb 02 ’24. After the transaction, the SVP & Chief Commercial Officer now owns 37,962 company shares. In a previous transaction on Jan 26 ’24, Paggiarino Dario A. sold 49,325 shares at 25.66 per share. EYPT shares that Chief Medical Officer owns now total 36,505.
Among the insiders who sold shares, Jones David Scott disposed of 26,017 shares on Jan 26 ’24 at a per-share price of $25.38. This resulted in the SVP & Chief Commercial Officer holding 37,962 shares of EYPT after the transaction. In another insider transaction, Jones David Scott sold 600 shares at $25.00 per share on Jan 25 ’24. Company shares held by the SVP & Chief Commercial Officer now total 37,962.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, EYPT has a high of $30.99 and a low of $3.36.
As of this writing, EYPT has an earnings estimate of $EyePoint Pharmaceuticals, Inc. per share for the current quarter. EPS was calculated based on a consensus of PYPT estimates, with a high estimate of $ENPT per share and a lower estimate of $VanEck Egypt Index ETF.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. EYPT’s latest balance sheet shows that the firm has $211.56M in Cash & Short Term Investments as of fiscal 2021. There were $39.20M in debt and $23.66M in liabilities at the time. Its Book Value Per Share was $5.43, while its Total Shareholder’s Equity was $184.38M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for EYPT is Buy with a score of 5.00.
